JOGO Health Closes $5.5M in Round Led by Hourglass Ventures, Extends Investment Opportunity for Public to Invest Alongside Mayo Clinic Ventures
19 June 2024 - 1:00AM
Business Wire
By leveraging the brain’s natural
neuroplasticity, JOGO Health’s AI-powered patented technology is
transforming the treatment of chronic pain and neuromuscular
disorders for millions worldwide.
JOGO Health (JOGO), a medtech company treating chronic pain and
neuromuscular disorders, announced it has closed over $5.5 million
in an investment round led by Hourglass Ventures. Due to high
demand, the company is opening the round to public retail investors
via a Regulation CF community investment round on Wefunder,
inviting retail investors to join alongside firms like Mayo Clinic
Ventures, the venture arm of the world-renowned hospital.
JOGO's wearable technology and app leverage the brain's natural
neuroplasticity to provide non-invasive, drug-free relief for
conditions including chronic lower back pain, stroke recovery,
migraines, and incontinence. Cleared by the FDA and reimbursed by
Medicare and commercial insurance, JOGO is expanding a $380B market
without drugs or surgery, supported by 18 patent claims across all
neuromuscular conditions. JOGO has already treated 25,000+ patients
across 50+ hospital channel partners, including Mayo Clinic, Mount
Sinai Hospital, and Brigham and Women's Hospital.
Led by a team of accomplished healthcare entrepreneurs, JOGO’s
team brings experience from Columbia University, Harvard
University, Yale University, AT&T, Johnson & Johnson, and
Astrazeneca. Co-Founder and CEO Sanjai Murali built JOGO from zero
to FDA market authorization. Siva Nadarajah, President and
Co-Founder, previously sold an AI healthcare startup to leading
clinical research company IQVIA, delivering a 10x return to
investors.
"The conviction of our investors is phenomenal," added Siva
Nadarajah, President and Co-Founder. "This round will enable us to
meet growing demand.”
"We believe healthcare is too important to be controlled by a
few," said Sanjai Murali, CEO and Co-Founder. “JOGO is founded on
the vision of 'by the world, for the world,' and opening our
investment round to retail investors on Wefunder is a crucial step
towards realizing this vision."
Capital raised will support JOGO’s commercial launch, putting
JOGO on track to become the first line of treatment for chronic
pain and other neuromuscular disorders - impacting 1 in 5 people
globally. The community investment round is open to everyone via
Wefunder, with a minimum investment of $100.
For more information about JOGO Health and to invest, visit
wefunder.com/jogohealth.
About JOGO Health:
JOGO Health is a medtech company treating chronic pain and
neuromuscular disorders, including stroke, migraines, and
incontinence. Cleared by the FDA and reimbursed by Medicare and
commercial insurance, JOGO’s wearable technology and app leverage
the brain’s natural neuroplasticity to offer relief from pain and
aid recovery from neuromuscular conditions, expanding a $380B
market without drugs or surgery. JOGO has already treated 25,000+
patients and completed 100,000+ sessions across 50+ hospital
partners, including Mayo Clinic and Mount Sinai. The company is
backed by leading investors Mayo Clinic Ventures and Hourglass
Ventures. For more information, please visit jogohealth.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618410008/en/
Sanjai Murali, CEO and Co-Founder
sanjai.murali@jogohealth.com